What are the side effects of VK2735?
The most commonly reported VK2735 side effects are nausea (most common, usually mild to moderate), vomiting, diarrhea or constipation. Most are mild and tend to be dose dependent. It is generally avoided with class-based caution (VK2735 has no FDA label yet): personal or family history of medullary thyroid carcinoma or MEN-2. Human clinical evidence for VK2735 is limited, so this reflects reported and observed effects, not a complete safety profile.
Reported VK2735 side effects
- Nausea (most common, usually mild to moderate)
- Vomiting
- Diarrhea or constipation
- Reduced appetite strong enough to cut protein intake too far
- In the oral Phase 2, GI effects drove notable dropouts (around a quarter of participants overall, more at the highest dose)
Who should avoid it
- Class-based caution (VK2735 has no FDA label yet): personal or family history of medullary thyroid carcinoma or MEN-2
- Class-based caution / likely trial exclusion: pancreatitis history
- Pregnancy / nursing
Bloodwork worth tracking
- Lipid panel
- Liver enzymes (ALT/AST)
- A1C if metabolic context
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on VK2735
Last updated 2026-06-15.